MX2021015961A - Moleculas novedosas. - Google Patents
Moleculas novedosas.Info
- Publication number
- MX2021015961A MX2021015961A MX2021015961A MX2021015961A MX2021015961A MX 2021015961 A MX2021015961 A MX 2021015961A MX 2021015961 A MX2021015961 A MX 2021015961A MX 2021015961 A MX2021015961 A MX 2021015961A MX 2021015961 A MX2021015961 A MX 2021015961A
- Authority
- MX
- Mexico
- Prior art keywords
- novel molecules
- compositions
- compounds
- viral
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 abstract 1
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
- C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
- C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902231A AU2019902231A0 (en) | 2019-06-26 | Novel molecules | |
| AU2019904862A AU2019904862A0 (en) | 2019-12-20 | Novel molecules (2) | |
| PCT/AU2020/050660 WO2020257870A1 (en) | 2019-06-26 | 2020-06-26 | Novel molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015961A true MX2021015961A (es) | 2022-03-22 |
Family
ID=74059610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015961A MX2021015961A (es) | 2019-06-26 | 2020-06-26 | Moleculas novedosas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220388950A1 (https=) |
| EP (1) | EP3990428A4 (https=) |
| JP (2) | JP2022539091A (https=) |
| KR (1) | KR20220050873A (https=) |
| CN (2) | CN121045535A (https=) |
| AU (1) | AU2020302839B2 (https=) |
| BR (1) | BR112021025630A8 (https=) |
| CA (1) | CA3142501A1 (https=) |
| IL (1) | IL289266B1 (https=) |
| MX (1) | MX2021015961A (https=) |
| NZ (1) | NZ783377A (https=) |
| WO (1) | WO2020257870A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2618842T3 (da) | 2010-09-22 | 2019-07-01 | Ena Therapeutics Pty Ltd | Hidtil ukendt immunstimulerende fremgangsmåde |
| EP3728289B1 (en) | 2017-12-21 | 2025-09-10 | Axelia Oncology Pty Ltd | Optimised compounds |
| KR20220050873A (ko) | 2019-06-26 | 2022-04-25 | 악셀리아 온콜로지 피티와이 리미티드 | 신규한 분자 |
| EP4157255A4 (en) * | 2020-05-26 | 2024-07-03 | Ena Respiratory Pty Ltd | CORONAVIRUS TREATMENT |
| WO2021258154A1 (en) | 2020-06-26 | 2021-12-30 | Axelia Oncology Pty Ltd | Branched lipid compounds |
| EP4395762A1 (en) * | 2021-09-02 | 2024-07-10 | Ena Respiratory Pty Ltd | Formulation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1239876B1 (en) | 1999-11-19 | 2008-07-30 | Csl Limited | Hcv vaccine compositions |
| EP2000144A1 (en) | 2000-05-19 | 2008-12-10 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds |
| EP1382352A1 (de) | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein-Konjugate und deren Verwendung |
| BR0313101A (pt) | 2002-08-12 | 2005-06-28 | Queensland Inst Med Res | Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso |
| EP2301972A1 (en) | 2002-08-12 | 2011-03-30 | The Council Of The Queensland Institute Of Medical Research | Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
| US20060002941A1 (en) | 2004-01-23 | 2006-01-05 | Vievax Corp. | Compositions comprising immune response altering agents and methods of use |
| WO2005079419A2 (en) | 2004-02-17 | 2005-09-01 | The Regents Of The University Of California | Methods of treating immunopathological disorders |
| GB0405634D0 (en) | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
| CN102614510A (zh) | 2004-10-18 | 2012-08-01 | 全球免疫股份有限公司 | 基于酵母的对慢性丙型肝炎感染的治疗 |
| EP1666056A1 (en) | 2004-12-06 | 2006-06-07 | Bestewil Holding B.V. | Cancer vaccine vesicles |
| NZ556004A (en) | 2004-12-21 | 2010-05-28 | Vaxinnate Corp | Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein |
| BRPI0607605A2 (pt) | 2005-02-08 | 2009-09-15 | Queensland Inst Med Res | moléculas imunogênicas |
| AU2006216822A1 (en) | 2005-02-22 | 2006-08-31 | Daniel Rachmilewitz | Methods of treating gastrointestinal inflammation |
| EP1787660A1 (en) * | 2005-11-22 | 2007-05-23 | GBF Gesellschaft für Biotechnologische Forschung mbH | New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions |
| US20070224205A1 (en) | 2006-03-07 | 2007-09-27 | Powell Thomas J | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| WO2008085549A2 (en) | 2006-07-28 | 2008-07-17 | Board Of Regents Of The University Of Texas System | Compositions and methods for stimulation of lung innate immunity |
| AU2014202674B2 (en) * | 2007-05-04 | 2014-08-14 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
| EP2200638B1 (en) | 2007-10-09 | 2016-03-16 | The University of Melbourne | Compositions for the transfection of cells |
| WO2009137103A2 (en) | 2008-05-09 | 2009-11-12 | Ourth Donald D | Anti-cancer/anti-viral compounds and methods of use |
| WO2009155332A1 (en) | 2008-06-17 | 2009-12-23 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
| EP2334332A4 (en) | 2008-09-05 | 2013-01-09 | Id Biomedical Corp Quebec | NEW COMPOSITIONS AND NEW ADJUVANTS |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| ES2534947T3 (es) | 2009-03-25 | 2015-04-30 | The Board Of Regents Of The University Of Texas System | Composiciones para la estimulación de resistencia inmunitaria innata de mamíferos a patógenos |
| WO2010115229A1 (en) | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| GB0907989D0 (en) | 2009-05-08 | 2009-06-24 | Hybrid Systems Ltd | Multivalent adjuvant display |
| EP2338521A1 (en) | 2009-12-28 | 2011-06-29 | Helmholtz-Zentrum für Infektionsforschung GmbH | Lipopeptide- and lipoprotein-conjugates and its use |
| AU2011232421B2 (en) * | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| DK2618842T3 (da) | 2010-09-22 | 2019-07-01 | Ena Therapeutics Pty Ltd | Hidtil ukendt immunstimulerende fremgangsmåde |
| JP6240077B2 (ja) * | 2011-10-06 | 2017-11-29 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 |
| WO2014207708A2 (en) | 2013-06-28 | 2014-12-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| WO2016037240A1 (en) | 2014-09-12 | 2016-03-17 | The University Of Melbourne | Immunological reagent |
| US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| JP2016216593A (ja) | 2015-05-19 | 2016-12-22 | 株式会社リコー | 反応材、熱交換器及びケミカルヒートポンプ |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| EP3419962A4 (en) | 2016-02-26 | 2020-03-11 | Auckland Uniservices Limited | CONJUGATES OF AMINO ACIDS AND PEPTIDES AND CONJUGATION METHOD |
| US20200147028A1 (en) | 2017-03-31 | 2020-05-14 | Ena Therapeutics Pty Ltd | Treatment of respiratory infection with a tlr2 agonist |
| NL2018803B1 (en) * | 2017-04-27 | 2018-11-05 | Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc | Adjuvant compounds |
| KR20200058424A (ko) * | 2017-08-30 | 2020-05-27 | 오클랜드 유니서비시즈 리미티드 | 펩티드 접합체, 접합 방법, 및 그의 용도 |
| US20210177795A1 (en) | 2017-12-21 | 2021-06-17 | Ena Therapeutics Pty Ltd | Administering compounds |
| EP3728289B1 (en) * | 2017-12-21 | 2025-09-10 | Axelia Oncology Pty Ltd | Optimised compounds |
| KR20220050873A (ko) * | 2019-06-26 | 2022-04-25 | 악셀리아 온콜로지 피티와이 리미티드 | 신규한 분자 |
| US20220347146A1 (en) | 2019-09-04 | 2022-11-03 | Axelia Oncology Pty Ltd | Cancer treatment |
| WO2021042171A1 (en) | 2019-09-04 | 2021-03-11 | Ena Therapeutics Pty Ltd | Cancer immunotherapy |
| EP4157255A4 (en) | 2020-05-26 | 2024-07-03 | Ena Respiratory Pty Ltd | CORONAVIRUS TREATMENT |
-
2020
- 2020-06-26 KR KR1020227000399A patent/KR20220050873A/ko active Pending
- 2020-06-26 CA CA3142501A patent/CA3142501A1/en active Pending
- 2020-06-26 WO PCT/AU2020/050660 patent/WO2020257870A1/en not_active Ceased
- 2020-06-26 NZ NZ783377A patent/NZ783377A/en unknown
- 2020-06-26 CN CN202511161213.7A patent/CN121045535A/zh active Pending
- 2020-06-26 US US17/622,451 patent/US20220388950A1/en active Pending
- 2020-06-26 BR BR112021025630A patent/BR112021025630A8/pt unknown
- 2020-06-26 MX MX2021015961A patent/MX2021015961A/es unknown
- 2020-06-26 EP EP20833003.5A patent/EP3990428A4/en active Pending
- 2020-06-26 AU AU2020302839A patent/AU2020302839B2/en active Active
- 2020-06-26 CN CN202080046587.3A patent/CN114174260B/zh active Active
- 2020-06-26 JP JP2021577007A patent/JP2022539091A/ja active Pending
-
2021
- 2021-12-22 IL IL289266A patent/IL289266B1/en unknown
-
2023
- 2023-03-23 US US18/112,091 patent/US12017979B2/en active Active
-
2025
- 2025-04-09 JP JP2025064409A patent/JP2025108536A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ783377A (en) | 2026-03-27 |
| CN114174260B (zh) | 2025-09-05 |
| EP3990428A1 (en) | 2022-05-04 |
| CN121045535A (zh) | 2025-12-02 |
| BR112021025630A8 (pt) | 2023-04-11 |
| EP3990428A4 (en) | 2023-07-19 |
| JP2025108536A (ja) | 2025-07-23 |
| US20220388950A1 (en) | 2022-12-08 |
| AU2020302839B2 (en) | 2025-08-14 |
| CA3142501A1 (en) | 2020-12-30 |
| US12017979B2 (en) | 2024-06-25 |
| BR112021025630A2 (pt) | 2022-02-15 |
| AU2020302839A1 (en) | 2022-01-20 |
| WO2020257870A1 (en) | 2020-12-30 |
| IL289266B1 (en) | 2026-03-01 |
| IL289266A (en) | 2022-02-01 |
| JP2022539091A (ja) | 2022-09-07 |
| CN114174260A (zh) | 2022-03-11 |
| KR20220050873A (ko) | 2022-04-25 |
| US20230257345A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015961A (es) | Moleculas novedosas. | |
| MX2020013853A (es) | Compuestos innovadores. | |
| UY38428A (es) | Nuevos compuestos antihelmínticos | |
| MX2023007852A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2020008772A (es) | Conjugados de il-15, y sus usos. | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| CL2018002826A1 (es) | Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| BR112017028413A2 (pt) | peptídeos antimicrobianos estabilizados | |
| CL2020001147A1 (es) | Compuestos antibacterianos | |
| GEAP202215303A (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| CL2016001364A1 (es) | Moduladores de ror gamma (rory) | |
| MX2018001075A (es) | Agentes terapeuticos y profilacticos antibacterianos. | |
| MX2016009449A (es) | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). | |
| CL2020000050A1 (es) | Compuestos que afectan la producción de pigmentos y su uso para el tratamiento de enfermedades bacterianas. | |
| BR112018014794A2 (pt) | pirimidinas substituídas com arila para uso em infecção pelo vírus influenza | |
| CL2017002482A1 (es) | Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
| MX364942B (es) | Peptidos antimicrobianos. | |
| BR112016016853A2 (pt) | Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso | |
| CY1118399T1 (el) | Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c | |
| MX2020009733A (es) | Composiciones. | |
| AR106981A1 (es) | Una composición antimicrobiana | |
| CL2017002451A1 (es) | Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
| MX2019006768A (es) | Peptidos antimicrobianos. | |
| MX392976B (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2019002248A (es) | Proteina de union al factor h modificada. |